# Cryo-Cell (CCEL) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/CCEL
## Company Profile
- Ticker: CCEL
- Exchange: AMEX
- Sector: Biopharma
- Location: United States
## Stock Data
- Close: 4.26 USD
- Market cap: 27306958.5 USD
- Last updated: 2026-09-08
## Business Overview
### Cord Blood and Tissue Banking
Cryo-Cell International, founded in 1989, is one of the earliest private cord blood banks. Together with affiliated organizations, it has stored more than 250,000 cord blood and cord tissue samples, generating revenue from processing and long-term storage services.
### Private Family Banking
Cryo-Cell’s core service allows families to preserve newborn cord blood and cord tissue for potential future medical use. Revenue includes initial collection and processing fees as well as recurring long-term storage fees.
### Public Cord Blood Banking
Cryo-Cell also operates a public banking program with Duke University and maintains a donation site at Cedars-Sinai Medical Center. The public bank has supported more than 900 transplants.
### Quality Systems and Processing Technology
The company’s facilities are FDA-registered, operate under cGMP and cGTP standards, and hold multiple state licenses and quality accreditations, including AABB and FACT. Cryo-Cell also holds exclusive rights to PrepaCyte-CB, its advanced cord blood processing technology.
## Why The Stock Is Moving

As of Sep 8, 2026, CCEL closed down 0.47% at $4.26. No new same-company headline was identified in the current news window.

## Future Catalysts

- Cryo-Cell’s catalysts are cord-blood banking, fertility services, and steady recurring consumer-health demand. The company moves more on operations than on binary events.

## Recent News
- 2026-07-15 20:30 EST — [Cord Blood Banking Leader Cryo-Cell Reports Fiscal Second Quarter 2026 Financial Results](https://biopharmsignal.com/news/CCEL/cord-blood-banking-leader-cryo-cell-reports-fiscal-second-quarter-2026-financial-7072363c) — Source: Cryo-Cell
- 2026-05-08 20:00 EST — [Cryo-Cell Receives Acceptance of Compliance Plan From NYSE American](https://biopharmsignal.com/news/CCEL/cryo-cell-receives-acceptance-of-compliance-plan-from-nyse-american) — Source: Cryo-Cell
- 2026-04-28 20:00 EST — [Cryo-Cell International Receives FACT Re-accreditation, Setting the Longest Independently Validated Quality Track Record Among U.S. Private Cord Blood Banks](https://biopharmsignal.com/news/CCEL/cryo-cell-international-receives-fact-re-accreditation-setting-the-longest-independently-validated-quality-track-record-among-u-s-private-cord-blood-banks) — Source: Cryo-Cell
- 2026-04-14 21:00 EST — [Cord Blood Banking Leader Cryo-Cell Reports Fiscal First Quarter 2026 Financial Results](https://biopharmsignal.com/news/CCEL/cord-blood-banking-leader-cryo-cell-reports-fiscal-first-quarter-2026-financial-results) — Source: Cryo-Cell
- 2026-03-12 21:00 EST — [Cryo-Cell Receives NYSE American Continued Listing Notice](https://biopharmsignal.com/news/CCEL/cryo-cell-receives-nyse-american-continued-listing-notice) — Source: Cryo-Cell